Article

Determination of the practical utility of ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): mapping OncoKB level 1 alterations using ESCAT

2026-05-20

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> The European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT) ranks genomic alterations by the evidence supporting the predictive value of the molecular target for response to targeted therapies. No openly available, systematically curated set of standard care biomarkers mapped to the ESCAT framework exists to support clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3fedb79f-21af-5a0b-af26-0096b0aafda9
DOI: 10.64898/2026.05.16.26353390

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Determination of the practical utility of ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): mapping OncoKB level 1 alterations using ESCATDOI 10.64898/2026.05.16.26353390Read

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Semantic proximity Read

Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.Semantic proximity Read

Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.Semantic proximity Read

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Semantic proximity Read

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.Semantic proximity Read

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologySemantic proximity Read

Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study.Semantic proximity Read

The molecular tumor board—a key element of precision oncologySemantic proximity Read

Clinical Use of Precision Oncology Decision SupportSemantic proximity Read

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrationsSemantic proximity Read

Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Semantic proximity Read

Novel clinical trial designs emerging from the molecular reclassification of cancerSemantic proximity Read